![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Sun Pharmaceutical Industries Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Pentoxifylline, Site-II, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2016-159 - Rev 00
This Chemical Type CEP, issued on January 09, 2017, remains in force until June 14, 2022, ensuring its reliability within the pharmaceutical industry.
Substance Number 851 associated with this CEP further emphasizes